BioCentury
ARTICLE | Clinical News

Xeomin incobotulinumtoxinA regulatory update

January 4, 2016 8:00 AM UTC

FDA approved an sBLA from Merz for Xeomin incobotulinumtoxinA to treat upper limb spasticity in adults. Xeomin is marketed in the U.S. to treat cervical dystonia, blepharospasm and glabellar lines. Th...